The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Swanson, Christine R ^a,b   Joers, Valerie ^a,b   Bondarenko, Viktoriya ^a   Brunner, Kevin ^a   Simmons, Heather A ^a   Ziegler, Toni E ^a   Kemnitz, Joseph W ^a,b   Johnson, Jeffrey A ^a,b   Emborg, Marina E ^a,b,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; PIOGLITAZONE; PLACEBO; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DOPAMINE; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DISABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; FEMALE; INFLAMMATION; INFLAMMATORY CELL; MACACA MULATTA; MALE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; RATING SCALE; ANIMAL; BRAIN; CORPUS STRIATUM; CYTOLOGY; DRUG POTENTIATION; HISTOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SUBSTANTIA NIGRA;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CORPUS STRIATUM; DOPAMINE; FEMALE; HYPOGLYCEMIC AGENTS; INFLAMMATION; MACACA MULATTA; MALE; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PLACEBOS; PPAR GAMMA; RANDOM ALLOCATION; SUBSTANTIA NIGRA; THIAZOLIDINEDIONES; TYROSINE 3-MONOOXYGENASE;

EID: 79961103714     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-91     Document Type: Article

References (62)

1. Kemnitz J, Elson D, Roecker E, Baum S, Bergman R, Meglasson M. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 1994, 43:204-211. 10.2337/diabetes.43.2.204, 8288044.
2. Sood V, Colleran K, Burge MR. Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2000, 2:429-440. 10.1089/15209150050194297, 11467345.
3. Ferrari CC, Tarelli R. Parkinson's disease and systemic inflammation. Parkinsons Dis 2011, 2011:1-9.
4. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397. 10.1016/S1474-4422(09)70062-6, 19296921.
5. Barnum CJ, Tansey MJ. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Progress in Brain Research 2010, 184:113-132. Cenci MA: Elsevier, Bjorkland A.
6. Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm 2010, 117:971-979. 10.1007/s00702-010-0428-1, 20571837.
7. Swanson CR, Sesso SL, Emborg ME. Can we prevent parkinson's disease?. Front Biosci 2009, 14:1642-1660.
8. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169:453-459. 10.1677/joe.0.1690453, 11375115.
9. Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. J Neurochem 2008, 106:506-518. 10.1111/j.1471-4159.2008.05388.x, 18384649.
10. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G. Inflammation induces mitochondirial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007, 100:1375-1386. 10.1111/j.1471-4159.2006.04327.x, 17254027.
11. Hunter RL, Choi DY, Ross SA, Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008, 432:198-201. 10.1016/j.neulet.2007.12.019, 2699576, 18207323.
12. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002, 82:615-624. 10.1046/j.1471-4159.2002.00990.x, 12153485.
13. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NFkappa B and iNOS activation. J Neurochem 2004, 88:494-501.
14. Emborg ME. Nonhuman primate models of Parkinson's disease. ILAR J 2007, 48:339-355.
15. Barcia C, Sanchez-Bahilla A, Fernandez-Villalba E, Bautista V, Poza Y, Poza M, Fernandez-Barreiro A, Hirsch EC, Herrero MT. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 years after MPTP exposure. Glia 2004, 46:402-409. 10.1002/glia.20015, 15095370.
16. McGeer P, Schwab C, Parent A, Doudet D. Presence of Reactive Microglia in Monkey Substantia Nigra Years after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Administration. Ann Neurol 2003, 54:599-604. 10.1002/ana.10728, 14595649.
17. Doudet DJ, Holden JE, Jivan S, McGeer E, Wyatt RJ. In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 2000, 38:105-113. 10.1002/1098-2396(200011)38:2<105::AID-SYN1>3.0.CO;2-S, 11018784.
18. Capitanio JP, Emborg ME. Contributions of non-human primates to neuroscience research. Lancet 2008, 371:1126-1135. 10.1016/S0140-6736(08)60489-4, 18374844.
19. London AJ, Kimmelman J, Emborg ME. Research ethics. Beyond access vs. protection in trials of innovative therapies. Science 2010, 328:829. 10.1126/science.1189369, 20466907.
20. Emborg-Knott ME, Domino EF. MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. Exp Neurol 1998, 152:829-830.
21. Bezard E. A call for clinically driven experimental design in assessing neuroprotection in experimentla Parkinsonism. Behavioral Pharmacology 2006, 17:379-382.
22. Emborg ME. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods 2004, 139:121-143. 10.1016/j.jneumeth.2004.08.004, 15488225.
23. Emborg ME, Moirano J, Schafernak KT, Moirano M, Evans M, Konecny T, Roitberg B, Ambarish P, Mangubat E, Ma Y, et al. Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiol Dis 2006, 23:281-289. 10.1016/j.nbd.2006.03.010, 16766201.
24. Emborg M, Moirano J, Raschke J, Bondarkenko V, Zufferey R, Peng S, Ebert AD, Joers V, Roitberg B, Holden J, et al. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 2009, 36:303-311. 10.1016/j.nbd.2009.07.022, 2989601, 19660547.
25. Emborg ME, Ma SY, Mufson EJ, Levee A, Holden JE, Brown D, Kordower JH. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 1998, 401:253-265. 10.1002/(SICI)1096-9861(19981116)401:2<253::AID-CNE7>3.0.CO;2-X, 9822152.
26. West MJ, Ostergaard K, Andreassen OA, Finsen B. Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method. J Comp Neurol 1996, 370:11-22. 10.1002/(SICI)1096-9861(19960617)370:1<11::AID-CNE2>3.0.CO;2-O, 8797153.
27. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolutely number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991, 54:30-33. 10.1136/jnnp.54.1.30, 1014294, 2010756.
28. Sripalakit P, Neamhom P, Saraphanchotiwitthaya A. High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 843:164-169. 10.1016/j.jchromb.2006.05.032, 16815107.
29. Hofmann CA, Edwards C, Hillman RM, Colca JR. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinology 1992, 130:735-740. 10.1210/en.130.2.735, 1733721.
30. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Megura K, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 1990, 40:156-162.
31. Physician's Desk Reference 2008, Montvale: Thomson Healthcare, 64.
32. Eberling JL, Bankiewicz KS, Jordan S, Van Brocklin HF, Jagust WJ. PET studies of functional compensation in a primate modle of Parkinson's disease. NeuroReport 1997, 8:2727-2733. 10.1097/00001756-199708180-00017, 9295108.
33. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen E, Palfi S, Roitberg B, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773. 10.1126/science.290.5492.767, 11052933.
34. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 2002, 941:1-10. 10.1016/S0006-8993(02)02480-0, 12031542.
35. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem Pharmacol 2005, 70:177-188. 10.1016/j.bcp.2005.03.033, 15925327.
36. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Madarino LJ, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87:2784-2791. 10.1210/jc.87.6.2784, 12050251.
37. Kawamori R, Matsuhisa M, Kinoshita J, Mochizuki K, Niwa M, Arisaka T, Ikeda M, Kubota M, Wada M, Kanda T, et al. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose updtake in non-insulin dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract 1998, 41:35-43. 10.1016/S0168-8227(98)00056-4, 9768370.
38. Palacios JM, Wiederhold KH. Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP), a compound producing pakrinsonism in humans, stimulates, [2-14C]deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains. Brain Res 1984, 301:187-191. 10.1016/0006-8993(84)90422-0, 6610458.
39. Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Kopin IJ, Sokoloff L. Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. Brain Res 1988, 453:227-234. 10.1016/0006-8993(88)90162-X, 3261197.
40. Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, Virley DJ. The PPAR-gamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol 2008, 154:226-233. 10.1038/bjp.2008.78, 2438969, 18332857.
41. Markey SP, Schmuff NR. The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds. Med Res Rev 1986, 6:389-429. 10.1002/med.2610060402, 3534484.
42. Johannessen JN, Chiueh CC, Burns RS, Markey SP. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci 1985, 36:219-224. 10.1016/0024-3205(85)90062-1, 3871242.
43. Yang SC, Johannessen JN, Markey SP. Metabolism of [14C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative neurotoxin. Chem Res Toxicol 1988, 1:228-233. 10.1021/tx00004a007, 2979736.
44. Mandel S, Weinreb O, Amit T, Youdim MB. Mechanisms of neuroprotective actions of the anti-Parkinsonian drug resagilline and its derivitives. Brain Research Reviews 2005, 48:379-387. 10.1016/j.brainresrev.2004.12.027, 15850677.
45. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease. Movement Disorders 2009, 24:564-573. 10.1002/mds.22402, 19086083.
46. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARgamma agonist piogltiazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV7171. Brain 2005, 128(Pt 6):1442-1453.
47. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002, 51:694-702. 10.1002/ana.10206, 12112074.
48. Peiris M, Monteith GR, Roberts-Thomson SJ, Cabot PJ. A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies. J Neurosci Methods 2007, 163:245-254. 10.1016/j.jneumeth.2007.03.013, 17477973.
49. Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes = Horn K, Landreth GE, Schurmann B, Zimmer A, Heneka MT. The oral antidiabetic pioglitazone protects from neurodegenerative and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005, 25:7805-7812. 10.1523/JNEUROSCI.2038-05.2005, 16120782.
50. Okada K, Yamashita T, Tsuji S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-suceptible EL mice. Brain Res 2006, 1102:175-178. 10.1016/j.brainres.2006.04.108, 16806109.
51. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ogawa H, Kim-Mitsuyama S. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007, 38:3016-3022. 10.1161/STROKEAHA.107.486522, 17885259.
52. Xu M, Wei C, Qin AP, Liu CF, Hong LZ, Zhao XY, Liu J, Qin ZH, Zhang HL. Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor kappa-B signaling pathway. Neuroscience 2010, 176:381-395.
53. Park SW, Yi JH, Miranpuri G, Satriomoto I, Bowen KK, Resnick DK, Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007, 320:1002-1012.
54. Geldmacher DS, Frollich L, Doody RS, Erkinjunti T, Vella B, Jones RW, Banerjee S, Lin P, Sano M. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 2006, 10:417-429.
55. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of piogltiazone in treatment of patients with Alzheimer disease. Arch Neurol 2011, 68:45-50. 10.1001/archneurol.2010.229, 20837824.
56. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gama agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging
57. Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffrey DR, Stefoski D, Katsamkis G, Feinstein DL. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol 2009, 211:124-130. 10.1016/j.jneuroim.2009.04.011, 19446890.
58. Shukla DK, Kaiser CC, Stebbins GT, Feinstein DL. Effects of pioglitazone on diffusion tensor imaging indicies in multiple sclerosis patients. Neurosci Lett 2010, 472:153-156. 10.1016/j.neulet.2010.01.046, 20144689.
59. Boris M, Kaiser CC, Goldblatt A, Elice MW, Edelson SM, Adams JB, Feinstein DL. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation 2007, 4:3. 10.1186/1742-2094-4-3, 1781426, 17207275.
60. Insulin Resistance Intervention after Stroke. , http://clinicaltrials.gov/ct2/show/NCT00091949?term=NCT00091949&rank =1
61. Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) (PNA). , http://www.clinicaltrials.gov/ct2/show/NCT00919555?term=ALS+and+pioglita zone&rank=1
62. Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept (ACTFRIE). , http://clinicaltrials.gov/ct2/show/NCT00811681